Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Area of Science:

• Mycology
• Antimicrobial Susceptibility Testing
• Clinical Microbiology

Background:

• Accurate susceptibility testing of Cryptococcus neoformans is crucial for effective antifungal therapy.
• Standardized methods are needed to ensure reproducible minimum inhibitory concentration (MIC) determination.
• Previous studies have identified variability in testing conditions impacting results.

Purpose of the Study:

• To define optimal test conditions for Cryptococcus neoformans antifungal susceptibility testing using a microtiter system.
• To evaluate the impact of different media, incubation times, and inoculum sizes on MIC values.
• To establish a simple, accurate, and reproducible method for routine testing.

Main Methods:

• Twenty-one Cryptococcus neoformans isolates were tested.
• Four chemically defined media (YNB 7, RPMI 1640, SAAMF, YNB 5.4) were evaluated.
• Incubation periods of 24 and 48 hours, and inoculum sizes ranging from 10^3 to 10^5 cells/mL were assessed.
• MICs for fluconazole, amphotericin B, and flucytosine were determined.

Main Results:

• Optimal growth and reproducibility were achieved with a 48-hour incubation period.
• An initial inoculum of 10^4 cells/mL was found to be optimal across tested media.
• Yeast nitrogen base (BYNB 7) medium yielded reproducible MICs, while SAAMF resulted in higher MICs.
• Amphotericin B showed low MIC variance, unlike fluconazole and flucytosine.

Conclusions:

• A microtiter system using BYNB 7, 48-hour incubation, and 10^4 cells/mL inoculum provides a simple, accurate, and reproducible method for C. neoformans susceptibility testing.
• This optimized method is suitable for determining susceptibility to fluconazole, amphotericin B, and flucytosine.
• Standardization of these parameters is essential for reliable antifungal susceptibility data.